Gilead touts new data for fast-growing Biktarvy as older HIV meds show some cracks

gilead4
Gilead is riding the success of HIV med Biktarvy as its HIV portfolio and overall sales dwindle. (Gilead)

Amid Gilead Sciences' flagging sales, HIV med Biktarvy has been a rare shining light with growth nearly quadrupling in the last year. Hoping to capitalize on its next-gen HIV portfolio's success, Gilead it touting new data for Biktarvy and Truvada follow-up Descovy that could help pad their cases. 

Biktarvy measured up to two treatment regimens, including archrival ViiV Healthcare's Tivicay, in suppressing symptoms of HIV in newly treated patients at the 144-week mark, according to data from two phase 3 clinical trials released Wednesday. 

Gilead said in a statement the two studies helped reinforce Biktarvy's strength in newly diagnosed patients.

Free Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This webinar will discuss the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

The drug once again showed it's "an effective treatment that offers durable viral suppression and maintains a high barrier to resistance,” said Diana Brainard, Gilead's senior VP for HIV and emerging viruses. “These longer-term data reaffirm Biktarvy’s role as a first-line treatment option.”

RELATED: Gilead's ready to spend big on Descovy, filgotinib launches as hep C and Yescarta struggle: CEO

Suggested Articles

Compared with the FDA "boxed warning," the EMA version puts a smaller restriction on the higher dose but broadens the cautionary language.

Shionogi's newest antibiotic Fetroja has now earned the FDA's approval, but will a mortality-rate warning scuttle the drug's chances?

Novartis' Sandoz doubled down in Japan as Lupin retreated. Dr. Reddy's posted a loss tied to its Zantac recall. Aslan's varlitinib failed again.